ERBB2 and breast cancer: In a separate trial testing the combination of CFI‐402257 and paclitaxel, safety and preliminary efficacy results were recently presented from 29 HER2− BC patients, including 90% HR+ of whom 75% had previously been treated with CDK4/6i.195, 196